High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS | Zendy

Hui-Min Chang | Zendy; HungChin Tsai | Zendy; Susan ShinJung Lee | Zendy; Calvin M. Kunin | Zendy; PeiChin Lin | Zendy; Shue-Ren Wann | Zendy; Yao-Shen Chen | Zendy

Open Access

High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS

Author(s) -

Hui-Min Chang,

HungChin Tsai,

Susan ShinJung Lee,

Calvin M. Kunin,

PeiChin Lin,

Shue-Ren Wann,

Yao-Shen Chen

Publication year - 2016

Publication title -

journal of the chinese medical association

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.535

H-Index - 42

eISSN - 1728-7731

pISSN - 1726-4901

DOI - 10.1016/j.jcma.2016.01.007

Subject(s) - medicine , trimethoprim , rash , hazard ratio , confidence interval , sulfamethoxazole , proportional hazards model , pneumonia , adverse effect , retrospective cohort study , pneumocystis pneumonia , pneumocystis jirovecii , antibiotics , microbiology and biotechnology , biology

Trimethoprim/sulfamethoxazole (TMP/SMX) is currently the most effective therapeutic agent for Pneumocystis jirovecii pneumonia (PJP) in patients with AIDS. The major drawback is the frequent occurrence of adverse reactions (ADRs).The current study was designed to determine the frequency and risk factors for TMP/SMX-related ADRs among patients with PJP and AIDS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research